| Literature DB >> 28703634 |
Thuy Nguyen-Thi-Dieu1, Huong Le-Thi-Thu2, Sy Duong-Quy3,4,5.
Abstract
Objective To determine the leucocyte profile and cytokine concentrations in the peripheral blood of children with an acute asthma exacerbation (AAE). Methods This descriptive, cross-sectional study enrolled paediatric patients admitted to hospital for AAE. The severity of AAE was assessed using the paediatric asthma score (PAS). Peripheral blood samples were collected for automatic quantification of white blood cell counts, CD3+, CD4+, and CD8+ T cells populations by flow cytometry and cytokine concentrations by flow cytometry-assisted immunoassay. Results A total of 127 children with AAE and 30 healthy control subjects were included in the study. The proportion of paediatric patients with decreased CD3+, CD4+ and CD8+ T cells was significantly higher in those with severe AAE compared with those with mild-to-moderate AAE. The concentrations of interleukin (IL)-2, IL-8, IL-12, and IL-4 in paediatric patients with rhinovirus infection were significantly higher than in those without rhinovirus infection. IL-2, IL-4, IL-6, TNF-α and GM-CSF concentrations during AAE were significantly lower than control. IL-5 and IL-13 concentrations during AAE were significantly higher than control. Conclusions The decrease of CD3+, CD4+, CD8+ T cells and IL-2, IL-4, IL-6, TNF-α, and GM-CSF combined with the increase of IL-5 and IL-13, were associated with AAE in children with asthma.Entities:
Keywords: Asthma; CD+ T cells; cytokine; exacerbation; hypereosinophilia
Mesh:
Substances:
Year: 2017 PMID: 28703634 PMCID: PMC5805192 DOI: 10.1177/0300060516680439
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Demographic and clinical characteristics of children with acute asthma exacerbation (AAE) (n = 127) who participated in this study to characterize the inflammatory cell profile and cytokine concentration in the peripheral blood during AAE.
| Characteristics | Frequency[ | Proportion (%) | |
|---|---|---|---|
| Age | |||
| <2 years | 24 | 18.9 | |
| 2–5 years | 58 | 45.7 | |
| >5 years | 45 | 35.4 | |
| Sex | |||
| Male | 83 | 65.4 | |
| Female | 44 | 34.6 | |
| Atopic allergy | |||
| Eczema | 46 | 37.4 | |
| Allergic rhinitis | 86 | 69.9 | |
| Food | 12 | 9.8 | |
| Others | 13 | 10.6 | |
| Rhinovirus infection | |||
| Positive | 64 | 54.7 | |
| Negative | 53 | 45.3 | |
| PAS | |||
| Mild | 12 | 9.4 | |
| Moderate | 52 | 40.9 | |
| Severe | 63 | 49.6 | |
| Length of hospital stay | |||
| Classified by days | |||
| 1–3 days | 41 | 32.3 | |
| >3–5 days | 59 | 46.5 | |
| >5 days | 27 | 21.3 | |
| Classified by PAS | Days | Statistical significance[ | |
| Mild | 5.0 ± 1.5 | NS | |
| Moderate | 4.5 ± 2.0 | ||
| Severe | 5.0 ± 2.0 | ||
Data presented as n of patients (%) or mean ± SD.
Baseline data missing for some patients.
Kruskall–Wallis test.
PAS, paediatric asthma score (mild 5–7, moderate 8–11, severe 12–15); NS, no significant between-group differences (P ≥ 0.05).
Leucocyte profile classified by the paediatric asthma score (PAS) for the acute asthma exacerbation.
| Cell types | PAS | Statistical significance[ | ||||
|---|---|---|---|---|---|---|
| Mild | Moderate | Severe | Total | |||
| Leucocytes | Normal | 4 (33.3) | 12 (23.1) | 8 (12.7) | 24 (18.9) | NS* |
| Increased[ | 8 (66.7) | 40 (76.9) | 55 (87.3) | 103 (81.1) | ||
| Eosinophils | Normal | 7 (58.3) | 35 (70.0) | 42 (70.0) | 84 (68.9) | NS* NS** NS*** |
| Increasedc | 5 (41.7) | 15 (30.0) | 18 (30.0) | 38 (31.1) | ||
| Neutrophils | Normal | 7 (58.3) | 21 (40.4) | 15 (23.8) | 43 (33.9) | NS* |
| Increasedd | 5 (41.7) | 31 (59.6) | 48 (76.2) | 84 (66.1) | ||
Data presented as n of patients (%).
Kruskall–Wallis test; *moderate versus mild; **severe versus mild; ***severe versus moderate.
>10 × 103/mm3; c>4%; d>45% for children <5 years and >65% for children ≥5 years.
Data missing for five patients.
Paediatric asthma score: mild 5–7, moderate 8–11, severe 12–15.
NS, no significant between-group difference (P ≥ 0.05).
T lymphocyte profile classified by the paediatric asthma score (PAS) for the acute asthma exacerbation.
| T lymphocyte subgroups | PAS | Statistical significance[ | |||
|---|---|---|---|---|---|
| Mild-to-moderate | Severe | Total | |||
| CD3+ | Normal | 16 (76.2) | 15 (50.0) | 31 (60.8) | |
| Decreased[ | 5 (23.8) | 15 (50.0) | 20 (39.2) | ||
| CD4+ | Normal | 13 (65.0) | 14 (46.7) | 27 (54.0) | |
| Decreased[ | 7 (35.0) | 16 (53.3) | 23 (46.0) | ||
| CD8+ | Normal | 20 (95.2) | 21 (72.4) | 41 (82.0) | |
| Decreasedd | 1 (4.8) | 8 (27.6) | 9 (18.0) | ||
Data presented as n of patients (%).
Z-test; severe versus mild-to-moderate asthma exacerbation.
Decreased CD3+ T cells: <2500 for <1 year, <2100 for 1–2 years, <1400 for >2 and ≤6 years, <1200 for >6 and ≤12 years, <100 for >12 years.
Decreased CD4+ T cells: <1400 for <1 year, <1300 for 1–2 years, <700 for >2 and ≤6 years, <650 for >6 and ≤12 years, <530 for >12 years.
Decreased CD8+ T cells: <500 for <1 year, <620 for 1–2 years, <490 for >2 and ≤6 years, <370 for >6 and ≤12years, <330 for >12 years.
Profile of cytokine levels in patients during and after the acute asthma exacerbation compared with healthy control subjects.
| Cytokines | Patients with acute asthma
exacerbation | Control group | Statistical significance[ | |
|---|---|---|---|---|
| During | After | |||
| Cytokines related to type 1 helper T cells and regulatory T cells, pg/ml | ||||
| IL-2 | 0.16 (0.05–44.02) | 0.16 (0.11–5.90) | 0.51 (0.11–67.86) | NS* |
| IL-8 | 5.07 (1.50–88.37) | 4.11 (2.23–346.80) | 5.07 (0.75–29.62) | NS*,** |
| IL-10 | 2.35 (0.01–399.78) | 2.21 (0.32–10.27) | 1.52 (0.30–43.00) | NS*,** |
| IL-12 | 0.01 (0.01–11.98) | 0.01 (0.01–5.82) | 0.01 (0.01–1.83) | NS*,** |
| IFN-γ | 12.41 (0.21–1056.32) | 12.41 (2.77–170.43) | 12.40 (2.76–1477.20) | NS*,** |
| TNF-α | 0.43 (0.21–249.91) | 0.67 (0.10–393.92) | 1.46 (0.32–44.46) | NS* |
| Cytokines related to type 2 helper T cells, pg/ml | ||||
| IL-4 | 0.02 (0.01–2.80) | 0.16 (0.11–5.9) | 0.51 (0.11–67.86) | |
| IL-5 | 1.49 (0.01–2.80) | 0.02 (0.01–1.11) | 0.08 (0.02–14.58) | |
| IL-6 | 0.30 (0.03–40.90) | 0.97 (0.03–16.62) | 1.03 (1.03–36.63) | NS¥
|
| IL-13 | 2.08 (0.07–33.88) | 0.10 (0.10–5.87) | 1.24 (0.09–5.89) | |
| GM-CSF | 0.91 (0.21–717.85) | 0.91 (0.22–109.51) | 5.73 (0.91–198.30) | NS* |
Data presented as median (min–max).
Kruskall–Wallis test; during versus after acute asthma exacerbation; **during and after acute asthma exacerbation versus control; ‡during versus control group; ¥after versus control; NS, no significant between-group difference (P ≥ 0.05).
IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
Cytokine concentrations in patients with or without rhinovirus (RV) infection.
| Cytokines | Patients with acute asthma
exacerbation | Statistical significance[ | |
|---|---|---|---|
| RV+ | RV– | ||
| Cytokines related to type 1 helper T cells and regulatory T cells, pg/ml | |||
| IL-2 | 0.25 (0.10–44.02) | 0.16 (0.05–38.78) | |
| IL-8 | 5.97 (2.08–88.37) | 3.46 (1.50–21.96) | |
| IL-10 | 2.35 (0.03–48.61) | 2.75 (0.01–399.78) | NS |
| IL-12 | 0.81 (0.01–11.98) | 0.01 (0.01–5.59) | |
| INF-γ | 12.41 (0.21–1056.32) | 12.41 (2.43–642.50) | NS |
| TNF-α | 0.43 (0.21–230.19) | 0.63 (0.27–249.91) | NS |
| Cytokines related to type 2 helper T cells, pg/ml | |||
| IL-4 | 1.14 (0.01–2.80) | 0.02 (0.01–1.39) | |
| IL-5 | 2.11 (0.07–9.49) | 0.90 (0.05–7.87) | NS |
| IL-6 | 1.03 (0.03–7.24) | 0.06 (0.03–40.09) | NS |
| IL-13 | 3.01 (0.07–33.88) | 1.67 (0.10–5.87) | NS |
| GM-CSF | 5.73 (0.21–717.85) | 0.91 (0.21–137.42) | NS |
Data presented as median (min–max).
Mann–Whitney U-test.
IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; NS, no significant between-group difference (P ≥ 0.05).
Cytokine concentrations during acute asthma exacerbation classified by the paediatric asthma score (PAS) for the acute asthma exacerbation.
| Cytokines | PAS | ||
|---|---|---|---|
| Mild | Moderate | Severe | |
| Cytokines related to type 1 helper T cells and regulatory T cells, pg/ml | |||
| IL-2 | 0.16 (0.05–13.86) | 0.16 (0.05–44.02) | 0.16 (0.10–15.99) |
| IL-8 | 5.20 (2.68–21.96) | 5.01 (2.08–21.90) | 5.07 (1.50–88.37) |
| IL-10 | 2.06 (0.07–78.07) | 2.71 (0.01–57.97) | 2.19 (0.03–48.61) |
| IL-12 | 0.45 (0.01–11.98) | 0.01 (0.01–8.63) | 0.02 (0.01–9.56) |
| INF-γ | 12.41 (2.43–461.45) | 22.41 (2.43–642.50) | 12.41 (0.21–1056.32) |
| TNF-α | 0.33 (0.32–95.70) | 0.43 (0.27–249.91) | 0.43 (0.21–230.19) |
| Cytokines related to type 2 helper T cells, pg/ml | |||
| IL-4 | 0.01 (0.01–1.85) | 0.02 (0.01–1.89) | 0.02 (0.01–2.80) |
| IL-5 | 0.82 (0.28–8.17) | 1.81 (0.07–6.85) | 1.49 (0.05–9.49) |
| IL-6 | 0.53 (0.03–4.85) | 0.06 (0.03–40.90) | 0.72 (0.03–30.20) |
| IL-13 | 3.70 (0.19–4.87) | 1.81 (0.60–7.04) | 2.08 (0.07–33.88) |
| GM-CSF | 0.22 (0.21–233.21) | 0.91 (0.21–188.38) | 0.91 (0.21–717.85) |
Data presented as median (min–max).
Kruskall–Wallis test; no significant between-group differences (P ≥ 0.05).
Paediatric asthma score: mild 5–7, moderate 8–11, severe 12–15.
IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.